Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Provention Bio (PRVB) Stock Price, News & Analysis

Provention Bio logo

About Provention Bio Stock (NASDAQ:PRVB)

Advanced Chart

Key Stats

Today's Range
$24.98
$24.98
50-Day Range
$23.74
$24.98
52-Week Range
$3.18
$25.00
Volume
218,200 shs
Average Volume
2.28 million shs
Market Capitalization
$2.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

PRVB Stock News Headlines

Macrogenics Inc MGNX
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
Sanofi completes Provention Bio acquisition
See More Headlines

PRVB Stock Analysis - Frequently Asked Questions

Provention Bio, Inc. (NASDAQ:PRVB) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.08. The company earned $0.68 million during the quarter, compared to analyst estimates of $3.75 million. Provention Bio had a negative net margin of 880.69% and a negative trailing twelve-month return on equity of 103.36%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Provention Bio investors own include NVIDIA (NVDA), NIO (NIO), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Meta Platforms (META), VBI Vaccines (VBIV) and Amarin (AMRN).

Company Calendar

Last Earnings
11/04/2021
Today
6/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRVB
Fax
N/A
Employees
82
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$113.57 million
Net Margins
-880.69%
Pretax Margin
-984.54%

Debt

Sales & Book Value

Annual Sales
$12.90 million
Price / Cash Flow
N/A
Book Value
$1.40 per share
Price / Book
17.84

Miscellaneous

Free Float
82,365,000
Market Cap
$2.37 billion
Optionable
Not Optionable
Beta
2.47
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:PRVB) was last updated on 6/5/2025 by MarketBeat.com Staff
From Our Partners